65,437 trials
HIV Infections · Cytomegalovirus Infections
Primary: Change in %CD38+ Human Leukocyte Antigen-D-related (HLA-DR)+ CD8+ T Cells From Baseline to Week 8. — 1.3; -4.0 percentage of activated T cells
Chronic Wounds
Primary: Resolution of Signs and Symptoms of Local Wound Infection/Inflammation. — 8 participants
Meningococcal Meningitis
Primary: Percentages of Subjects With Serum Bactericidal Titer ≥ 1:8 Against N.Meningitidis Serogroup C — 83; 92 Percentages of subjects
Cystic Fibrosis
Primary: Uniformity of Aerosol Distribution — -0.05; 0.10 ratio — p=0.07
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) or Death — 101; 28; 19; 2 Participants
Blood Pressure
Primary: BP Measurements Using the Reference Auscultatory Sphygmomanometer — 186; 107; 93; 53 mmHg
Cystic Fibrosis · Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With a Pulmonary Exacerbation Requiring IV Antibiotics or Hospitalization — 24; 26; 29; 21 number of participants — p=0.86
Postmenopausal Osteoporosis
Primary: Ratio of Pharmcokinetic (PK) Area Under the Concentration Time Curve (AUC) Parameter Estimates Between Day 16 (Midazolam With the Presence of Denosumab) and Day 1…
HIV-1 Infection
Primary: Change in CD8+ T-cell Activation From Baseline to Week 4 — 0.00; 0.64 percentage HLA-DR+/CD38+ of CD8+ — p=0.028
Hunter Syndrome · Mucopolysaccharidosis II · MPS II
Primary: Safety Evaluation — 28; 0; 0; 16 participants
Psoriasis
Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001
Cocaine Dependence
Primary: Evidence of Abstinence From Cocaine as Indicated by Qualitative Urinalysis for Benzoylecgonine. — 2; 1 participants
Knee Injury
Primary: MRI to Evaluate Success of Outcome. — 88.6 units on a scale
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Average Eye IOP — 26.16; 25.98; 26.26; 23.91 Millimeters of Mercury (mmHg)
Brain Tumor · Central Nervous System Tumor
Primary: Event-free Survival — 1; 1; 0; 0 participants